Latest news with #BreastCancerResearchFoundation
Yahoo
11-06-2025
- Entertainment
- Yahoo
Elizabeth Hurley gushes over ‘surprising' Billy Ray Cyrus romance: ‘We're so similar'
Elizabeth Hurley's new romance with Billy Ray Cyrus was a surprise to everyone but her. 'I think people found Billy and I being together a little surprising,' the supermodel exclusively told Page Six at the Breast Cancer Research Foundation's Hot Pink Party on Tuesday night. 'It's not surprising to me because we're actually quite similar and get on extremely well,' she continued, admitting that 'there has been quite a reaction.' Hurley, who was the host of the event, also shared what she has in common with the 'Achy Breaky Heart' singer. 'We both like to laugh a lot, and we both love the country,' the 'Austin Powers' actress said. 'And we both love country music, both love movies. We've got a lot in common — and cowboy boots, definitely,' she added. Hurley, 59, attended the party with her son, Damian, 23. She posed on the carpet in a stunning pink ruffled lace applique dress with a thigh-high slit. Pop superstar Sting performed at the New York event, which supports funding for breast cancer research. Hurley has been a longtime supporter of the organization. 'It's been wonderful,' Hurley told Page Six of the 30 years she's been global ambassador for the Estée Lauder Company's breast cancer campaign. 'It's been wonderful to really, really know every stride that's been made, be part of the people that are trying to make the changes and the progress,' the mom of one shared. 'It has become really one of the most important things in my life.' The swimwear designer also confessed to becoming emotional when taking the stage at the annual event. 'I always have to stop myself crying whenever I go on stage for the first time,' she explained. 'It's very moving because a lot of people in this audience have been affected by breast cancer. They're either going through treatment themselves or they've lost someone to breast cancer or other things that have happened to them. And it's very moving indeed to see them.' Hurley debuted her whirlwind romance with the 'Hannah Montana' actor with a PDA pic on April 20 after flying to Cyrus' epic Nashville estate for Easter. Before long, Hurley and Cyrus, 63, shared more photos of themselves riding off into the sunset in an off-road vehicle, cozying up for a 'Tennessee weekend' and passionately kissing during a quiet countryside walk. Cyrus later revealed that the duo, who worked together on 'Christmas in Paradise' in 2022, reconnected after Hurley reached out with an unexpected text amid his divorce from singer Firerose. 'Hey, it looks like life might be a little bit tough and just wanted you to know I'm in your corner; you've got a friend in your corner,' the text read, Cyrus told Apple Music Country's 'The Ty Bentli Show' in April. 'Of all the people to reach out to me in that second that maybe I needed most… this friend who made me laugh,' he said. An insider told Page Six last month that the swimsuit model was 'waiting a long time for romance.' 'I think she likes the whole cowboy thing,' they added. A separate source told us last month that Hurley's friends — including Rock legend Elton John — were confused by the unexpected pairing. 'Liz's friends think it must be a joke or madness, but they aren't saying it to her,' the source said. 'Elton may not understand this relationship, and is a bit bemused by it. But for all his faults, Elton is really loyal to Liz.' Hurley later called the aftermath of the relationship launch a 'helluva few weeks' in a subsequent Instagram post. 'Well…it's been a helluva few weeks since my glorious sojourn in the Maldives, but here are some of my happy memories,' she captioned several dreamy photos from a recent vacation in the sunny locale.
UPI
10-06-2025
- Entertainment
- UPI
Famous birthdays for June 10: Elizabeth Hurley, Hugh Dancy
1 of 2 | Elizabeth Hurley arrives on the red carpet at the Breast Cancer Research Foundation Hot Pink Party at the Glasshouse on May 13 in New York City. The model turns 60 on June 10. Photo by John Angelillo/UPI | License Photo
New York Post
02-06-2025
- Entertainment
- New York Post
‘Bachelorette' star Katie Thurston is losing her memory as she fights Stage 4 cancer
Katie Thurston is going through the wringer in her Stage 4 breast cancer battle. The 'Bachelorette' alum, 34, gave a heartbreaking health update in an Instagram video posted Sunday. 'I just finished my second month of treatment and if you're asking how long treatment is, technically forever,' Thurston told her followers. 'I am optimistic about medical advancements in the future — fingers crossed as a stage 4 girly.' 8 Katie Thurston in her Instagram video. thekatiethurston/Instagram 8 Katie Thurston gives an update on her cancer battle. thekatiethurston/Instagram 'But right now, after finishing two months of my medication, my hair is coming out in an unnatural amount of clumps,' the reality star shared. 'I'm losing my memory. That's great. Going through customs and them being like, 'Where are you coming from?' And I looked at him and I was like, 'I don't remember.'' Thurston explained that she recently got into a 'little disagreement' with her husband, comedian Jeff Arcuri, where she couldn't defend herself because of her memory issues. 8 Katie Thurston with her husband Jeff Arcuri. thekatiethurston/Instagram 'I was like, 'This has happened before,'' she recalled. 'He was like, 'When?' I was like, 'I don't know but I know it has!' We're able to laugh about it now.' 'Cancer is s–t,' Thurston continued. 'Sometimes I'm like, 'Stop feeling bad for yourself.' Other times I'm like, 'You're allowed to feel bad for yourself. Cancer f—ing sucks.'' 8 Katie Thurston in the hospital for cancer treatment. Instagram/@thekatiethurston 8 Katie Thurston on 'The Bachelorette' in 2021. ABC Thurston explained that she's reached the phase of her treatment where she has to make 'big decisions' about how to treat her liver. She said she's opted for histotripsy, which uses focused ultrasound to destroy cancer cells without cutting into the body. 'It's National Cancer Survivors Day,' she said. 'Every day that I'm alive, I'm a survivor. So go me, I guess.' 8 Katie Thurston at the 2025 Breast Cancer Research Foundation (BCRF) Hot Pink Party in New York. Andrew H. Walker/Shutterstock Thurston originally competed on Matt James' season of 'The Bachelor' in 2021 and then became the star of 'The Bachelorette' Season 17. One month before her intimate wedding to Acuri, 37, in New York City in March, Thurston publicly revealed her breast cancer diagnosis. 8 Katie Thurston in a selfie. Instagram/@thekatiethurston 'I experienced a range of emotions over the past two weeks. Despair. Anger. Sadness. Denial. And then strength. Purposeful. Ready. I cried a lot,' she said in a message on Instagram. In March, Thurston shared that her cancer had spread to her liver and was Stage 4. 8 Katie Thurston. Instagram/@thekatiethurston 'I know stage four can sound very scary, and it can be,' she said. 'However, given that I am triple positive and the spots on my liver are fairly small and detected early, I feel very optimistic on my outcome.' Thurston's cancer was discovered after she found a lump on her breast, which led to her getting a mammogram.
Business Wire
30-05-2025
- Health
- Business Wire
Updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) Recommend Use of FES PET Imaging for Lobular Breast Cancer
ARLINGTON HEIGHTS, Ill.--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for clinicians now recommend considering fluoroestradiol (FES) positron emission tomography (PET) for systemic staging in patients with recurrent or metastatic lobular breast cancer. GE HealthCare's Cerianna™ (fluoroestradiol F18) injection, available in the United States, is the only FDA-approved imaging agent for the detection of estrogen receptor positive (ER+) breast cancer metastases, including lobular breast cancer. The updated NCCN Guidelines ® expand the recommendation for the use of FES PET imaging in ER+ disease. In 2023, FES PET was included in the NCCN Guidelines for systemic staging of recurrent/stage IV ER+ breast cancer. According to the Breast Cancer Research Foundation, 95% of invasive lobular cancer (ILC) tumors are ER+. i ILC is the second most common type of breast cancer in the U.S., accounting for 10-15% of all breast cancers and an estimated 43,000 new cases each year. ii iii iv Lobular tumors typically do not form lumps which makes the cancer harder to detect with self-exams, mammography, ultrasound and magnetic resonance imaging (MRI). ILC can also recur more than a decade v after initial diagnosis and metastasize to unusual places such as the bones, brain, liver, lungs, gynecological organs, and others. vivii Once recurrent or metastatic lobular breast cancer is suspected, the new guidelines recommend considering FES PET imaging of the whole body to assess whether ER+ lobular tumors are present. 'Lobular cancers are often missed during routine screening, which can result in larger, more advanced tumors when they are finally detected and diagnosed,' said Jit Saini, MD, Chief Medical Officer of the Pharmaceutical Diagnostics (PDx) division of GE HealthCare. 'This NCCN Guidelines update is significant because it will give more oncologists the confidence to use Cerianna PET imaging for patients with lobular breast cancer. It may also facilitate broader insurance coverage so more patients with this common, but hard-to-detect cancer will have an opportunity to receive a comprehensive diagnosis that accelerates clinical decisions and early intervention.' Cerianna is a molecular imaging agent indicated for use with PET imaging for the detection of ER+ lesions as an adjunct to biopsy in patients with known or suspected recurrent or metastatic breast cancer. Cerianna works by binding to functional ER lesions and then the whole body is imaged by PET scan to help doctors assess and treat lobular breast cancer appropriately. With its diffuse growth patterns, detection and biopsy of ILC can be more difficult. Cerianna provides an alternative method to assess ER status across the whole body. The recommendation that FES PET may be appropriate in lobular histology was established by an expert working group convened by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and included breast care specialists from the SNMMI, Lobular Breast Cancer Alliance, American College of Nuclear Medicine and Korean Society of Nuclear Medicine. The SNMMI is a nonprofit organization that promotes the science, technology and practical application of nuclear medicine and molecular imaging. The National Comprehensive Cancer Network (NCCN ®) is a not-for-profit alliance of 33 leading U.S. cancer centers devoted to patient care, research, and education. The NCCN Guidelines are the recognized standard for clinical direction and policy in cancer care and the most thorough and frequently updated clinical practice guidelines available in any area of medicine. GE HealthCare's Pharmaceutical Diagnostics segment is a global leader in imaging agents used to support around 130 million procedures per year globally, equivalent to four patient procedures every second. Its Molecular Imaging portfolio combines established proprietary products across cardiology, neurology and oncology, with an innovative pipeline, all aimed at enabling better informed diagnosis and monitoring for improved therapy decision making and clinical outcomes. Learn more about Cerianna here: About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. IMPORTANT SAFETY INFORMATION FOR CERIANNA™ (FLUORESTRADIOL F18) INJECTION INDICATIONS AND USAGE: CERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. Limitations of Use: Tissue biopsy should be used to confirm recurrence of breast cancer and to verify ER status by pathology. CERIANNA is not useful for imaging other receptors, such as human epidermal growth factor receptor 2 (HER2) and the progesterone receptor (PR). Important Safety Information CONTRAINDICATIONS None. WARNINGS AND PRECAUTIONS Risk of Misdiagnosis Inadequate Tumor Characterization and Other ER-Positive Pathology Breast cancer may be heterogeneous within patients and across time. CERIANNA images ER and is not useful for imaging other receptors such as HER2 and PR. The uptake of fluoroestradiol F 18 is not specific for breast cancer and may occur in a variety of ER-positive tumors that arise outside of the breast, including from the uterus and ovaries. Do not use CERIANNA in lieu of biopsy when biopsy is indicated in patients with recurrent or metastatic breast cancer. False Negative CERIANNA Scan A negative CERIANNA scan does not rule out ER-positive breast cancer. Pathology or clinical characteristics that suggest a patient may benefit from systemic hormone therapy should take precedence over a discordant negative CERIANNA scan. Radiation Risks Diagnostic radiopharmaceuticals, including CERIANNA, expose patients to radiation. Radiation exposure is associated with a dose-dependent increased risk of cancer. Ensure safe drug handling and patient preparation procedures (including adequate hydration and voiding) to protect patients and health care providers from unintentional radiation exposure. Pregnancy Status Assessment of pregnancy status is recommended in females of reproductive potential before administering CERIANNA. ADVERSE REACTIONS In Clinical Trials (n=1207) the most common adverse reactions seen occurred at a rate < 1% were injection-site pain and dysgeusia. USE IN SPECIFIC POPULATIONS Pregnancy Risk Summary All radiopharmaceuticals, including CERIANNA, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of radiation dose. Advise a pregnant woman of the potential risks of fetal exposure to radiation from administration of CERIANNA. There are no available data on CERIANNA use in pregnant women. No animal reproduction studies using fluoroestradiol F 18 have been conducted to evaluate its effect on female reproduction and embryo-fetal development. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Lactation Risk Summary There are no data on the presence of fluoroestradiol F 18 in human milk, or its effects on the breastfed infant or milk production. Lactation studies have not been conducted in animals. Advise a lactating woman to avoid breastfeeding for 4 hours after CERIANNA administration in order to minimize radiation exposure to a breastfed infant. Pediatric Use The safety and effectiveness of CERIANNA in pediatric patients have not been established. Geriatric Use Clinical studies of fluoroestradiol F 18 injection did not reveal any difference in pharmacokinetics or biodistribution in patients aged 65 and over. DRUG INTERACTIONS Systemic Endocrine Therapies that Bind to ER Drugs that bind to the ER, including SERMs and SERDs, may compete with the binding of fluoroestradiol F18 and may reduce detection of ER-positive lesions with CERIANNA. Before administration of CERIANNA, discontinue drugs that bind to the ER, such as SERMs and SERDs, for at least 5 biological half-lives: (e.g. elacestrant for 11 days, tamoxifen for 8 weeks and fulvestrant for 28 weeks). Prior to Cerianna administration, please read the full Prescribing Information and additional Important Safety Information here. To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800 654 0118 (option 2 then option 1) or by email at or FDA at 800 FDA 1088 or JB11825US 2025
Associated Press
30-05-2025
- Business
- Associated Press
Updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommend Use of FES PET Imaging for Lobular Breast Cancer
ARLINGTON HEIGHTS, Ill.--(BUSINESS WIRE)--May 30, 2025-- GE HealthCare (Nasdaq: GEHC) today announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) for clinicians now recommend considering fluoroestradiol (FES) positron emission tomography (PET) for systemic staging in patients with recurrent or metastatic lobular breast cancer. GE HealthCare's Cerianna™ (fluoroestradiol F18) injection, available in the United States, is the only FDA-approved imaging agent for the detection of estrogen receptor positive (ER+) breast cancer metastases, including lobular breast cancer. The updated NCCN Guidelines ® expand the recommendation for the use of FES PET imaging in ER+ disease. In 2023, FES PET was included in the NCCN Guidelines for systemic staging of recurrent/stage IV ER+ breast cancer. This press release features multimedia. View the full release here: PET/CT scan with Cerianna™ (fluoroestradiol F18) injection for patient with ILC reveals bone metastases According to the Breast Cancer Research Foundation, 95% of invasive lobular cancer (ILC) tumors are ER+. i ILC is the second most common type of breast cancer in the U.S., accounting for 10-15% of all breast cancers and an estimated 43,000 new cases each year. iiiiiiv Lobular tumors typically do not form lumps which makes the cancer harder to detect with self-exams, mammography, ultrasound and magnetic resonance imaging (MRI). ILC can also recur more than a decade v after initial diagnosis and metastasize to unusual places such as the bones, brain, liver, lungs, gynecological organs, and others. vivii Once recurrent or metastatic lobular breast cancer is suspected, the new guidelines recommend considering FES PET imaging of the whole body to assess whether ER+ lobular tumors are present. 'Lobular cancers are often missed during routine screening, which can result in larger, more advanced tumors when they are finally detected and diagnosed,' said Jit Saini, MD, Chief Medical Officer of the Pharmaceutical Diagnostics (PDx) division of GE HealthCare. 'This NCCN Guidelines update is significant because it will give more oncologists the confidence to use Cerianna PET imaging for patients with lobular breast cancer. It may also facilitate broader insurance coverage so more patients with this common, but hard-to-detect cancer will have an opportunity to receive a comprehensive diagnosis that accelerates clinical decisions and early intervention.' Cerianna is a molecular imaging agent indicated for use with PET imaging for the detection of ER+ lesions as an adjunct to biopsy in patients with known or suspected recurrent or metastatic breast cancer. Cerianna works by binding to functional ER lesions and then the whole body is imaged by PET scan to help doctors assess and treat lobular breast cancer appropriately. With its diffuse growth patterns, detection and biopsy of ILC can be more difficult. Cerianna provides an alternative method to assess ER status across the whole body. The recommendation that FES PET may be appropriate in lobular histology was established by an expert working group convened by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and included breast care specialists from the SNMMI, Lobular Breast Cancer Alliance, American College of Nuclear Medicine and Korean Society of Nuclear Medicine. The SNMMI is a nonprofit organization that promotes the science, technology and practical application of nuclear medicine and molecular imaging. The National Comprehensive Cancer Network (NCCN ® ) is a not-for-profit alliance of 33 leading U.S. cancer centers devoted to patient care, research, and education. The NCCN Guidelines are the recognized standard for clinical direction and policy in cancer care and the most thorough and frequently updated clinical practice guidelines available in any area of medicine. GE HealthCare's Pharmaceutical Diagnostics segment is a global leader in imaging agents used to support around 130 million procedures per year globally, equivalent to four patient procedures every second. Its Molecular Imaging portfolio combines established proprietary products across cardiology, neurology and oncology, with an innovative pipeline, all aimed at enabling better informed diagnosis and monitoring for improved therapy decision making and clinical outcomes. Learn more about Cerianna here: About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. IMPORTANT SAFETY INFORMATION FOR CERIANNA™ (FLUORESTRADIOL F18) INJECTION INDICATIONS AND USAGE: CERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. Limitations of Use: Tissue biopsy should be used to confirm recurrence of breast cancer and to verify ER status by pathology. CERIANNA is not useful for imaging other receptors, such as human epidermal growth factor receptor 2 (HER2) and the progesterone receptor (PR). Important Safety Information CONTRAINDICATIONS WARNINGS AND PRECAUTIONS Risk of Misdiagnosis Inadequate Tumor Characterization and Other ER-Positive Pathology False Negative CERIANNA Scan Radiation Risks Pregnancy Status ADVERSE REACTIONS USE IN SPECIFIC POPULATIONS Pregnancy Risk Summary Lactation Risk Summary Pediatric Use Geriatric Use DRUG INTERACTIONS Systemic Endocrine Therapies that Bind to ER Prior to Cerianna administration, please read the full Prescribing Information and additional Important Safety Information here. To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800 654 0118 (option 2 then option 1) or by email at[email protected]or FDA at 800 FDA 1088 JB11825US 2025 View source version on CONTACT: GE HealthCare Media Contact: Emmy Elguizaoui Communications Director – USCAN [email protected] KEYWORD: ILLINOIS UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: TECHNOLOGY GENERAL HEALTH PROFESSIONAL SERVICES NEUROLOGY SCIENCE DATA ANALYTICS CARDIOLOGY BIOTECHNOLOGY HEALTH HEALTH TECHNOLOGY OTHER SCIENCE RESEARCH OTHER HEALTH RADIOLOGY DATA MANAGEMENT ARTIFICIAL INTELLIGENCE ONCOLOGY SOURCE: GE HealthCare Copyright Business Wire 2025. PUB: 05/30/2025 09:20 AM/DISC: 05/30/2025 09:18 AM
